Greenwich LifeSciences (GLSI) Expected to Release Quarterly Earnings on Friday

Greenwich LifeSciences (NASDAQ:GLSI) is expected to be announcing its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its earnings results on Tuesday, August 11th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.06. On average, analysts expect Greenwich LifeSciences to post ($1.29) EPS for the current fiscal year and ($1.17) EPS for the next fiscal year.

Greenwich LifeSciences Stock Down 2.7%

NASDAQ:GLSI opened at $16.07 on Wednesday. The stock has a market cap of $235.91 million, a PE ratio of -10.44 and a beta of 1.57. The business’s 50-day simple moving average is $16.57 and its two-hundred day simple moving average is $21.27. Greenwich LifeSciences has a 52 week low of $7.78 and a 52 week high of $34.10.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GLSI. Weiss Ratings downgraded Greenwich LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. HC Wainwright increased their price target on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Greenwich LifeSciences has an average rating of “Hold” and a consensus price target of $69.00.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies designed to reduce the risk of breast cancer recurrence. The company’s lead product candidate is GLSI-100, an investigational vaccine combining the HER2-derived peptide GP2 with granulocyte-macrophage colony-stimulating factor (GM-CSF). GLSI-100 is being developed as an adjuvant therapy for patients with HER2-positive breast cancer who have completed standard treatment, including trastuzumab.